These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 29628113)

  • 1. [Seasonal flu vaccination for older people: Evaluation of the adjuvanted vaccine. Positioning report].
    López Mongil R; López Trigo JA; Mariano Lázaro A; Mato Chaín G; Ramos Cordero P; Salleras Sanmartí L;
    Rev Esp Geriatr Gerontol; 2017 Nov; 52 Suppl 2():1-14. PubMed ID: 29628113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Seasonal flu vaccination for older people: Evaluation of the quadrivalent vaccine. Positioning report].
    López Trigo JA; López Mongil R; Mariano Lázaro A; Mato Chaín G; Moreno Villajos N; Ramos Cordero P
    Rev Esp Geriatr Gerontol; 2018 Sep; 53 Suppl 2():185-202. PubMed ID: 30107941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between adjuvanted and nonadjuvanted influenza vaccination among patients undergoing hemodialysis: A cost-effectiveness analysis from Thailand.
    Joob B; Wiwanitkit V
    Saudi J Kidney Dis Transpl; 2018; 29(2):474-475. PubMed ID: 29657224
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy.
    Iannazzo S
    J Prev Med Hyg; 2011 Mar; 52(1):1-8. PubMed ID: 21710816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
    Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
    J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
    Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
    Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Flu vaccination in the elderly].
    Mato Chaín G; Mariano Lázaro A; Alcudia Pérez F; Verdejo Bravo C
    Rev Esp Geriatr Gerontol; 2011; 46(2):89-95. PubMed ID: 21388712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 21-winter seasons retrospective study of antibody response after influenza vaccination in elderly (60-85 years old) and very elderly (>85 years old) institutionalized subjects.
    Nunzi E; Iorio AM; Camilloni B
    Hum Vaccin Immunother; 2017 Nov; 13(11):2659-2668. PubMed ID: 28922621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Economic and Health impact of influenza vaccination with adjuvant MF59 in population over 64 years in Spain].
    Pérez-Rubio A; Eiros JM
    Rev Esp Quimioter; 2018 Feb; 31(1):43-52. PubMed ID: 29355006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly.
    Levin Y; Kochba E; Shukarev G; Rusch S; Herrera-Taracena G; van Damme P
    Vaccine; 2016 Oct; 34(44):5262-5272. PubMed ID: 27667332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity, safety, and effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: A systematic review.
    Dos Santos G; Tahrat H; Bekkat-Berkani R
    Hum Vaccin Immunother; 2018; 14(8):1853-1866. PubMed ID: 29517396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children.
    Solares AR; Aragon CG; Pivaral RU; Prado-Cohrs D; Sales-Carmona V; Pellegrini M; Groth N
    J Infect Dev Ctries; 2014 Sep; 8(9):1160-8. PubMed ID: 25212080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
    Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
    Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M
    Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis.
    Beyer WE; Nauta JJ; Palache AM; Giezeman KM; Osterhaus AD
    Vaccine; 2011 Aug; 29(34):5785-92. PubMed ID: 21624411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines.
    Noh JY; Song JY; Choi WS; Lee J; Seo YB; Kwon YJ; Ko GJ; Cha DR; Kang YS; Lee YK; Cheong HJ; Kim WJ
    Hum Vaccin Immunother; 2016 Nov; 12(11):2902-2908. PubMed ID: 27802078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.